An Official Website of the United States Government
Company Information:
Name:
SENEX BIOTECHNOLOGY, INC.
Address:
715 Sumter Street
Columbia, SC 29208-
Columbia, SC 29208-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Inhibitors of disease-promoting activities of senescence
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Donald C. Porter
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): The proposed project is aimed at developing a novel class of drugs against chronic diseases associated with old age. Such agents act by inhibiting a newly discovered regulatory pathway that endows senescent cells with disease- promoting paracrine activities.… More
Small Molecules Inducing BTG1 Transcription
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$107,001.00
Abstract:
DESCRIPTION (provided by applicant): BTG1 is a transcription regulatory protein that interacts with different transcription factors and nuclear receptors. BTG1 acts as a tumor suppressor and as a mediator of myogenic and erythroid differentiation. BTG1 tra
nscription is positively regulated by… More
Inhibitors of disease-promoting activities of senescence
Award Year / Program / Phase:
2008 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Award Amount:
$802,501.00
Abstract:
DESCRIPTION (provided by applicant): This project is aimed at developing a new class of drugs, which act by inhibiting pathogenic activities of senescent cells. Cell senescence occurring as a result of aging or cellular damage, is associated with upregulat
ion and secretion of proteins implicated in… More
CDK3-inhibiting anticancer agents
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Donald C. Porter
Award Amount:
$107,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR project is aimed at developing a novel type of anticancer drugs, termed SNX9- class compounds. These compounds have a dual activity: (i) inhibition of a transcriptional regulatory pathway that endows g
rowth-arrested tumor cells and… More
CDK3-inhibiting anticancer agents
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Donald C. Porter – 803-777-6161
Award Amount:
$1,548,102.00
Abstract:
DESCRIPTION (provided by applicant): This Phase II SBIR project is aimed at developing a novel type of drugs, termed SNX9-class compounds, with a unique combination of two anticancer activities. The first is a selective antiproliferative effect on tumor cells relative to normal cells. The second is… More